News

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
Mesoblast extends payer coverage for Ryoncil to over 100M U.S. lives
Mesoblast (MESO) announced that it has continued to expand coverage for Ryoncil, the first mesenchymal stromal cell ...
The Manila Times8h
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable ...
Health News Florida9h
The FDA warns patients about counterfeit Ozempic that may be in circulation
The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...
Hits and Misses in RFK Jr.’s Comments on Food Dyes
In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has said that "very, very strong studies" link ...
Telix Pharmaceuticals Limited: IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...
Target baby food is recalled over lead contamination
A company that makes baby food sold under a Target store brand is recalling more than 25,000 packages of a product because it ...
Bristol Myers' heart disease drug fails to meet main goals in late-stage study (April 14)
The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...
Alston & Bird Allege Big Pharma Company Amgen Monopolized US Arthritis Drug Market
Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...
National Law Review1d
Post‑Chevron Spotlight: Federal Court Nixes FDA Rule Reclassifying Laboratory Services as Medical Devices
In another rebuke to federal regulatory overreach, the U.S. District Court for the Eastern District of Texas (“District Court ...
Biocon Biologics Ltd.: Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...